Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra tumoral autologous natural killer cell transfer
We have previously reported radiation induced sensitization of canine osteosarcoma (OSA) to natural killer (NK) therapy, including results from a first in dog clinical trial. Here, we report correlative analyses of blood and tissue specimens for signals of immune activation in trial subjects. Among 10 dogs treated with palliative radiotherapy (RT) and intra tumoral adoptive NK transfer, we performed ELISA on serum cytokines, flow cytometry for immune phenotype of PBMCs, and PCR on tumor tissue for immune related gene expression. We then queried The Cancer Genome Atlas (TCGA) to evaluate the association of cytotoxic/immune related gene expression with human sarcoma survival. Updated survival analysis revealed five 6 month survivors, including one dog who lived 17.9 months. Using feeder line co culture for NK expansion, we observed maximal activation of dog NK cells on day 17 19 post isolation with near 100% expression of granzyme B and NKp46 and high cytotoxic function in the injected NK product. Among dogs on trial, we observed a trend for higher baseline serum IL 6 to predict worse lung metastasis free and overall survival (P 0.08) PCR analysis revealed low absolute gene expression of CD3, CD8, and NKG2D in untreated OSA. Among treated dogs, there was marked heterogeneity in the expression of immune related genes pre and post treatment, but increases in CD3 and CD8 gene expression were higher among dogs that lived 6 months compared to those who did not. Analysis of the TCGA confirmed significant differences in survival among human sarcoma patients with high and low expression of genes associated with greater immune activation and cytotoxicity (CD3e, CD8a, IFN g, perforin, and CD122/IL 2 receptor beta) Updated results from a first in dog clinical trial of palliative RT and autologous NK cell immunotherapy for OSA illustrate the translational relevance of companion dogs for novel cancer therapies. Similar to human studies, analyses of immune markers from canine serum, PBMCs, and tumor tissue are feasible and provide insight into potential biomarkers of response and resistance.
PloS one